399 Blockade of the IL-12/IL-23 Pathway With Ustekinumab Modulates the Composition of the Microbiome in Lesional Skin From Psoriasis Patients

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2018.03.406
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Il-12; Il-23

Science-Business eXchange
2012English

Metabolic Parameters in Psoriatic Patients Treated With Interleukin-12/23 Blockade (Ustekinumab)

Journal of Dermatology
DermatologyMedicine
2017English

The Tale of IL-12 and IL-23: A Paradigm Shift

Journal of Immunology
AllergyImmunology
2019English

Retraction Statement: Metabolic Parameters in Psoriatic Patients Treated With Interleukin-12/23 Blockade (Ustekinumab)

Journal of Dermatology
DermatologyMedicine
2018English

Disrupting the IL-36 and IL-23/IL-17 Loop Underlies the Efficacy of Calcipotriol and Corticosteroid Therapy for Psoriasis

JCI insight
Medicine
2019English

461 Depletion of the Microbiome Using Broad-Spectrum Antibiotic Cocktail Improves the Psoriasiform Phenotype via Attenuation of TNFα and IL-23-IL-17A in Three Psoriasis Mouse Models

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Bacteriophage of the Skin Microbiome in Patients With Psoriasis and Healthy Family Controls

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2020English

IL-23-Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A

Journal of Immunology
AllergyImmunology
2010English

IL-12 and IL-27 Regulate the Phagolysosomal Pathway in Mycobacteria-Infected Human Macrophages

Cell Communication and Signaling
BiochemistryCell BiologyMolecular Biology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy